ChromaDex CDXC 深 沪
等待开盘 08-04 09:30:00 美东时间
7.87
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 7.87
- 总市值 6.12亿
- 52周最高 9.18
- 市盈率 静 71.94
- 换手率 0.00%
- 52周最低 2.305
- 委 比 0.00%
- 总股本 7775.04万
- 历史最高 23.66
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.15
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Niagen Bioscience Subsidiary Signs Supply Agreement
Niagen Bioscience ( ($NAGE) ) just unveiled an announcement. On July 25, 2025, ...
07-30 05:25
Niagen Bioscience Enters Exclusive License Agreement With Haukeland University Hospital, Securing Exclusive Rights To A Body Of Proprietary IP, Know-How And Data
Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a
07-08 20:35
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Celldex Therapeutics announced new data showing that barzolvolimab, a monoclonal antibody targeting KIT receptor, provides sustained complete responses and improved quality of life in patients with chronic spontaneous urticaria (CSU). At 76 weeks (7 months post-treatment), 41% of patients (150 mg Q4W) achieved complete response (UAS7=0), and 48% reported no CSU-related impact on their quality of life (DLQI=0/1). KIT-related tolerability events we...
06-12 22:01
Niagen Bioscience Reports Study Showing Niagen (NR) Boosts NAD+ Levels By 140% And Improves Clinical Markers In Werner Syndrome, Expanding Rare Disease Research Portfolio
Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner SyndromeNiagen Bioscience expands rare disease research portfolio,
06-09 20:35
Niagen Bioscience says Niagen IV is available in almost 600 clinics nationwide
Niagen Bioscience (NASDAQ:NAGE) announced on Monday the continued expansion of its clinical footprint, with additional new clinics now offering pharmaceutical-grade Niagen IV and injections featuring...
05-05 20:52
Chromadex Rebrands to Niagen Bioscience, Inc.
Chromadex ( ($CDXC) ) just unveiled an announcement. On March 19, 2025, ChromaD...
03-19 20:57
美股大行评级 | 花旗：维持爱科集团"中性"评级，目标价从95美元升至98美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1108674722736648193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从18美元升至19美元</p> <p>• Ascendiant Capital：维持Daxor Corp.(DXR)"买入"评级，目标
03-18 10:15
美股大行评级 | 杰富瑞：上调爱彼迎评级至"买入"，目标价从165美元升至185美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106138546093002753.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 瑞杰金融：上调Trevi Therapeutics(TRVI)评级至"强烈买入"，目标价从9美元升至29美元</p> <p>• Needham：维持Trevi Therapeutics(TRVI)"买入"评级，目标价从8美
03-11 10:13
美股大行评级 | 摩根大通：维持Alignment Healthcare"中性"评级，目标价从14美元升至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104689832132448256.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Chardan Capital：维持Ocugen(OCGN)"买入"评级，目标价从6美元升至7美元</p> <p>• Piper Sandler：维持ALX Oncology Holdings(ALXO)"超配"评级，目标
03-07 13:53
美股牛股 | Chimerix暴涨70%获溢价收购！加密货币股BKKT隔夜大涨超23%
Chimerix暴涨70%，获Jazz制药溢价收购！加密货币股BKKT隔夜大涨超23%，特朗普拟推加密货币战略储备>>
03-06 19:23
